PHENOM
5.5.2021 09:02:13 CEST | Business Wire | Press release
Phenom , the No. 1 provider of Talent Experience Management (TXM) solutions, has been recognized as a Strategic Leader in the 2021 Fosway 9-Grid™ for Talent Acquisition . Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to meet the needs of complex enterprise-scale customers. Additionally, these solutions achieve higher levels of customer impact and advocacy compared to alternatives in the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005153/en/
The Fosway Group 9-Grid™ report for Talent Acquisition indicates the relative position of solutions and providers in the European talent acquisition system space. Analyzing data from the pandemic-altered market, the 2021 report also indicates how well software solutions scaled and performed for customers during last year’s volatility.
The report identified several key market and solution trends, including:
- THE GREAT REBOARD: Companies that lost jobs last year are pivoting to better recruitment technology to prepare for strategic, efficient rehiring.
- CANDIDATE EXPERIENCE: Transparent communication and agile decision-making underlie positive candidate experiences for both hires and non-hires.
- ARTIFICIAL INTELLIGENCE: Enterprises must leverage AI and automation in the hiring process to remain competitive.
- DIVERSITY, EQUITY & INCLUSION : Employers are realizing that diversity, equity and inclusion commitments must be a centerpiece in their HR strategies.
- VIDEO EXPERIENCES : Live video’s role in hiring will last beyond the pandemic, as companies realize it will be an efficient, authentic way to find best-fit candidates.
- INTERVIEW SCHEDULING : Chatbot and AI reduce friction across the scheduling process, generating more meaningful interactions between candidates and recruiters.
- TALENT MARKETPLACE : The most effective solutions need to include gigs, reskilling and upskilling for mutual employer/employee growth.
- COLLABORATIVE HIRING : Increasing communication between recruiter and hiring manager workflows is encouraged through integrations with Microsoft Teams and Slack.
“Phenom’s focus on disrupting the candidate and hiring experiences, has resonated strongly with the market,” said David Wilson, CEO of Fosway. “Rapid growth in adoption in enterprise organisations, as well as expanded physical presence and multiple market acquisitions is further accelerating its success in Europe and globally. All of these warrant Phenom’s increased rating as a Strategic Leader for Talent Acquisition in 2021.”
In 2020, the Phenom platform was adopted by 25,000 recruiters, talent marketers and hiring managers — helping them hire over 2 million people and engage over 3 million employees.
The Phenom platform automates administrative tasks and personalizes experiences, generating more impactful moments throughout the talent journey. As a result, candidates find the right job faster; employees learn and evolve; recruiters discover best-fit talent with efficiency and scale; and managers make stronger data-driven decisions to build their future teams.
Kuehne+Nagel, a global logistics company and Phenom customer, continues to see new value in the Phenom platform every day.
“Through Phenom, we’ve been able to strengthen our centralized recruitment activities per hemisphere, build an external career site and adapt it to local markets, implement a CRM — and now level up our employee experience — to build the most sophisticated talent acquisition ecosystem there is to offer,” said Sandra Aasma, global HR systems expert at Kuehne+Nagel.
“As Phenom continues to expand across EMEA, we’re honored to be one of the first-ever Strategic Leaders in Fosway’s Talent Acquisition grid,” said Jeff Carey, senior vice president of international business at Phenom. “Our new position on the Fosway 9-grid™ signals that enterprises routinely pick Phenom — galvanized by our sophisticated AI-powered platform and steadfast commitment to customers. By constantly upgrading and launching new products, we always stay at the front of a rapidly evolving HR technology market.”
Over 100 companies across the EMEA market have adopted Phenom’s platform to upgrade their talent experiences. As demand for Talent Experience Management has spiked, Phenom recently acquired two Europe-based companies and opened an office in Munich to complement its European headquarters in Rotterdam. With over 100 employees based in countries including Germany, France, Ireland, the Netherlands, Switzerland, Italy, Spain and the United Kingdom, Phenom continues to solidify EMEA’s importance within the company’s ultimate growth strategy.
To learn more about Phenom’s Strategic Leader position, please visit their blog .
To see Fosway’s full analysis, check out their 2021 9-grid™ .
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalizes and automates the talent journey for candidates, recruiters, employees and management with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates and employees find the right job, recruiters identify and engage the right talent, and management optimizes HR strategy, process and spend. Phenom was ranked among the fastest-growing technology companies in the 2020 Deloitte Technology Fast 500, and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com . Connect with Phenom on LinkedIn , Twitter , Facebook , YouTube and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005153/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom